MTOR and breast cancer: In contrast, UBE2C knockdown leads to inhibition of proliferation and invasion in breast cancer cells, as well as a decrease of p-AKT, p-mTOR, and hypoxia-inducible factor 1-α (HIF-1α) and an increase of phosphorylated phosphatase and p-PTEN levels.